Browse the evidence

GLP-1 receptor agonists (semaglutide) and dual incretin agonists (tirzepatide) achieve 15-20% total body weight loss, rivaling the efficacy of bariatric surgery.

If you have obesity, these medications offer a powerful, non-surgical path to significant weight loss (15-20%). They require a weekly injection and likely lifelong use, but they can improve metabolic health and may be more accessible than surgery for some. Discuss with your doctor if you are a candidate.

GLP-1 receptor agonists (semaglutide and tirzepatide) produce significantly greater average weight loss (14.9% and 18.5%, respectively) than physicians estimate (9.22%), and are associated with high rates of gastrointestinal side effects (80-90%) that are significantly underestimated by prescribers.

If you are prescribing GLP-1 agonists, ensure you are counseling patients on the high likelihood of gastrointestinal side effects (up to 90%) and the significant magnitude of weight loss (15-18%). Underestimating these factors leads to poor adherence and unrealistic expectations.

Incretin medications (GLP-1 RAs and dual agonists) are the most effective class of AOMs for older adults, achieving 15-25% weight loss, but require careful titration to manage side effects.

Incretin drugs like Semaglutide and Tirzepatide are currently the most effective weight loss medications for older adults, often resulting in 15-25% body weight loss. They work by mimicking gut hormones to reduce hunger. Doctors usually start with a low dose to minimize side effects like nausea and gradually increase it.

Phentermine/topiramate and naltrexone/bupropion are effective alternative pharmacotherapies for weight loss (4-10%) in patients without cardiovascular contraindications, offering oral administration options.

If you cannot take or afford weekly injections, oral medications like phentermine/topiramate or naltrexone/bupropion are effective alternatives. They typically result in 4-10% weight loss. Side effects like nausea or insomnia are common but often improve over time, especially if you start with a low dose and increase slowly. These are not suitable if you have heart disease, high blood pressure, or a history of seizures.

Supplementation with 5g/day spinach-derived thylakoid membranes combined with a hypo-caloric diet significantly improves atherogenic indices (AIP, CRI-I, CRI-II) and insulin resistance surrogates (TyG-BMI, METS-IR) in obese women with PCOS compared to placebo.

If you have PCOS and are overweight, adding 5 grams of spinach thylakoid extract daily to your calorie-restricted diet may help improve your blood vessel health markers and insulin sensitivity more than dieting alone. Take it 30 minutes before lunch.

Tirzepatide (5, 10, or 15 mg once weekly) provides significantly longer continuous time in glycaemic control (HbA1c <7.0% and ≤6.5%) and sustained body weight reduction (≥5%) compared to placebo, semaglutide 1 mg, and insulin therapies in patients with type 2 diabetes.

For patients with Type 2 Diabetes, tirzepatide (5, 10, or 15 mg once weekly) offers significantly longer periods of stable blood sugar (HbA1c <7.0%) and sustained weight loss (≥5%) compared to placebo, semaglutide 1 mg, and insulin therapies. This suggests that tirzepatide may provide more durable disease management with fewer hypoglycaemic events than insulin.

Semaglutide (Ozempic/Wegovy) promotes significant weight loss (10-15% body weight) and improves glycemic control in adults with type 2 diabetes or obesity through GLP-1 receptor agonism, delayed gastric emptying, and appetite suppression.

Semaglutide is a once-weekly injection that mimics a gut hormone to slow digestion and reduce appetite. It is clinically proven to help people with obesity or type 2 diabetes lose 10-15% of their body weight when combined with diet and exercise. Side effects like nausea are common initially but often subside; starting with a low dose helps manage this. It is not a substitute for lifestyle changes but a tool to facilitate them.

Tirzepatide produces significantly greater weight loss than semaglutide and liraglutide in patients with obesity or type 2 diabetes.

If you are struggling with obesity or type 2 diabetes, tirzepatide (administered weekly at doses up to 15 mg) has demonstrated superior weight loss capabilities compared to semaglutide and liraglutide in clinical trials. To maximize results, combine this pharmacotherapy with lifestyle changes, including a caloric deficit, regular physical activity, and behavioral modifications.

GLP-1 receptor agonists (GLP-1RA) and related incretin mimetics (e.g., semaglutide, tirzepatide, retatrutide) produce significant weight loss in adults with obesity, achieving reductions comparable to bariatric surgery.

GLP-1 medications like Semaglutide and Tirzepatide are highly effective for weight loss, often achieving 15-24% body weight reduction, which rivals bariatric surgery. They work by increasing satiety and slowing digestion. Because obesity is chronic, these drugs likely need to be taken long-term to maintain weight loss. Side effects are mostly gastrointestinal (nausea), but serious risks exist for those with specific thyroid cancer histories. Consult a doctor to see if you are a candidate.

GLP-1 receptor agonists (specifically semaglutide and tirzepatide) produce substantial weight loss and metabolic improvements in patients with severe mental illness experiencing antipsychotic-induced weight gain, without exacerbating psychiatric symptoms.

For patients with severe mental illness struggling with antipsychotic-induced weight gain, GLP-1 receptor agonists like semaglutide offer a highly effective treatment option that reduces weight significantly without worsening mental health symptoms. While side effects like nausea are common, they are often mild and transient. The main barrier is often cost and insurance coverage, so patients and providers should advocate for access to these medications as a standard part of care for this population.

Sibutramine, an appetite suppressant acting on the hypothalamus, is more effective than placebo for weight loss when combined with lifestyle changes, with 22-38% of patients achieving >5% weight loss in 3 months.

Sibutramine helps you lose weight by reducing appetite. About 22-38% of users lose more than 5% of their body weight in 3 months. It is not safe for people with heart problems or high cardiovascular risk. Side effects include increased blood pressure and dry mouth.

Bupropion/Naltrexone combination therapy results in a mean weight loss of 6.1% over 56 weeks in obese or overweight adults, significantly better than placebo (1.3%).

Bupropion/Naltrexone helps you lose about 6% of your body weight over a year. It works by reducing appetite and food cravings. It is not safe for people with seizure disorders, uncontrolled high blood pressure, or those taking certain antidepressants. Side effects like nausea are common but often temporary.

Semaglutide (subcutaneous 1 mg/week and oral 14 mg/day) significantly reduces HbA1c and body weight in patients with type 2 diabetes, with subcutaneous administration showing superior efficacy compared to other GLP-1 receptor agonists.

Semaglutide is a highly effective GLP-1 receptor agonist for lowering blood sugar (HbA1c) and reducing body weight in type 2 diabetes patients. It is available in both weekly injections (1 mg) and daily oral tablets (14 mg), with the injection showing slightly greater efficacy. For obese non-diabetics, a higher injection dose (2.4 mg) leads to significant weight loss (~15%). While nausea is a common side effect, it is usually manageable. Patients with pre-existing eye disease (retinopathy) should use it cautiously due to a potential increased risk of retinal complications.

GLP-1 agonists (semaglutide, liraglutide, tirzepatide) produce significantly greater weight loss than placebo when combined with lifestyle modifications in adults and adolescents without type 2 diabetes.

If you have obesity and lifestyle changes haven't been enough, GLP-1 medications like semaglutide or tirzepatide are significantly more effective than placebo when combined with diet and exercise. Expect side effects like nausea, which are usually manageable, and commit to a treatment duration of at least 5-7 months to see full results.

GLP-1 receptor agonists (specifically semaglutide 2.4 mg/week and liraglutide 3.0 mg/day) produce significant weight loss in adults with obesity (BMI ≥27 or ≥30) when combined with lifestyle modifications, outperforming placebo and many other pharmacotherapies.

If you have obesity (BMI ≥30) or overweight (BMI ≥27) with comorbidities, GLP-1 agonists like semaglutide (2.4 mg weekly) or liraglutide (3.0 mg daily) are highly effective for weight loss when combined with diet and exercise. Semaglutide showed an average loss of 15.3 kg over 68 weeks in trials. Expect mild, temporary gastrointestinal side effects, but these rarely require stopping treatment. Oral options exist for those averse to injections.

GLP-1 receptor agonists (semaglutide 2.4 mg and liraglutide 3.0 mg) reduce energy intake by 34.5% and 13.0% respectively, leading to estimated body weight reductions of 17% and 8% at 20 weeks.

Clinical doses of GLP-1 agonists (semaglutide 2.4mg, liraglutide 3.0mg) significantly reduce energy intake, leading to substantial weight loss (8-17%) over 20 weeks. This effect is primarily driven by reduced food intake rather than just increased energy expenditure, and the model accounts for diminishing efficacy (tolerance) over time.

Tirzepatide (Mounjaro/Zepbound) is a dual GIP/GLP-1 receptor agonist that promotes weight loss and glycemic control through synergistic mechanisms including increased glucose-dependent insulin secretion, reduced glucagon, delayed gastric emptying, and increased satiety.

Tirzepatide is a powerful, weekly injectable medication for diabetes and obesity that works by mimicking hormones to control blood sugar and reduce appetite. It requires a prescription, medical supervision, and lifestyle changes (diet/exercise). Using it without medical oversight for aesthetic reasons is dangerous and contributes to drug shortages and fraud.

Dual incretin agonists (specifically GIP/GLP-1 co-agonists like tirzepatide) produce significantly greater weight loss and glycemic reduction than single GLP-1 receptor agonists, effectively closing the treatment gap between pharmacotherapy and bariatric surgery.

If standard GLP-1 medications (like semaglutide or liraglutide) are not delivering sufficient weight loss or blood sugar control, or if side effects prevent you from taking a higher dose, ask your doctor about dual agonists like tirzepatide. These medications target two hormones (GIP and GLP-1) simultaneously and have shown in clinical trials to produce significantly greater weight loss (up to 20%) and better blood sugar control than single-hormone drugs, often with a manageable side effect profile.

Tirzepatide, a dual GIP and GLP-1 receptor agonist, produces significant weight loss (15-21%) in adults with obesity when administered weekly alongside lifestyle modifications.

If you have obesity or are overweight with related health issues, Tirzepatide is a once-weekly injection that works by mimicking hormones to reduce appetite and slow digestion. In clinical trials, patients lost 15-21% of their body weight over 72 weeks when combining the drug with diet and exercise. While nausea and diarrhea are common side effects, they affect a minority of users. This treatment is intended for long-term management, not short-term fixes.

GLP-1 receptor agonists (semaglutide, liraglutide) and dual GIP/GLP-1 agonists (tirzepatide) induce significant weight loss (5-21%) by suppressing appetite via central nervous system mechanisms and delaying gastric emptying, serving as effective pharmacological alternatives to surgery.

If diet and exercise aren't enough, GLP-1 drugs like Semaglutide (Wegovy) or Tirzepatide (Zepbound) are highly effective pharmacological options. They work by mimicking gut hormones to reduce hunger signals in the brain and slow down digestion. Semaglutide is taken once weekly, while Tirzepatide (a dual agonist) can lead to even greater weight loss (up to 21%). These require a prescription and lifestyle changes, and may cause gastrointestinal side effects like nausea.

Tirzepatide treatment for weight management produces significant weight loss (mean 22.6% over 36 weeks) accompanied by perceived improvements in appetite control, energy levels, and physical functioning, with gastrointestinal side effects being common but generally manageable.

Tirzepatide is a weekly injection approved for weight management in adults with obesity or overweight. Clinical data from the SURMOUNT-4 trial shows an average weight loss of 22.6% over 36 weeks. Patients report significant improvements in appetite control, energy, and physical functioning. Common side effects include nausea and diarrhea, which are often manageable. Most patients found the injection device easy to use and were willing to continue treatment.

Subcutaneous semaglutide 2.4 mg administered once weekly significantly reduces body weight and cardiometabolic risk factors (HbA1c, total cholesterol, systolic blood pressure) in East Asian adults with obesity compared to placebo, though it is associated with higher rates of adverse events.

For East Asian adults with obesity, once-weekly subcutaneous semaglutide (2.4 mg) combined with diet and exercise is a clinically effective treatment for significant body weight reduction and improvement in cardiometabolic risk factors like blood pressure and cholesterol. Patients should be aware that adverse events are more common than with placebo, but the clinical benefits are established.

Tirzepatide (a dual GLP-1RA/GIP agonist) produces superior mean weight loss (18.4%) compared to other FDA-approved pharmacotherapies for obesity, including semaglutide, phentermine-topiramate, and orlistat.

If you have obesity and lifestyle changes alone haven't worked, Tirzepatide is currently the most effective FDA-approved medication for weight loss, showing nearly 18% average weight loss in clinical trials. It requires weekly injections and careful dose titration to manage gastrointestinal side effects, but it offers superior results compared to older drugs like Orlistat or Phentermine-Topiramate.

Semaglutide (a GLP-1RA) produces significant weight loss (10-12.5%) and improves cardiometabolic risk factors, making it more effective than older pharmacotherapies like Phentermine-Topiramate and Orlistat.

Semaglutide is a highly effective weekly injection for weight loss, averaging 10-12% loss in clinical trials. It is more effective than older drugs like Orlistat or Phentermine-Topiramate and also improves heart health markers. It requires weekly injections and titration to manage side effects.